Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026 Report Analysis & Data Highlights:
The identification of mitogen activated protein kinase (MAPK) signaling pathway and its critical role in the regulation of diverse cellular activities in the development of cancer including cell proliferation, survival, and differentiation have drawn the interest the researchers to inhibit the pathway as an alternative in the management of cancer. The MEK inhibitors were developed to specifically target the Ras/Ref/Me/Erk signaling pathway thus inhibiting cell proliferation, and inducing apoptosis.
To date, four MEK inhibitors have entered into the market which has shown high adoption rates by BRAF mutated cancer patients, mainly in melanoma. In addition to this, several other MEK inhibitors are present in the clinical trials. The potential candidates in the pipeline are AZD8330, NX-179, HL-085, E6201, Mirdametinib and Refametinib. These drugs have shown encouraging clinical response in their early studies and are expected to enter the market during the forthcoming years.
Apart from melanoma, several ongoing clinical trials are also ongoing which are accessing the role of MEK inhibitors in other cancers including non-small cell lung cancer, breast cancer, thyroid cancer, ovarian cancers and others. It is expected that the coming years will witness expanded approval of the approved MEK inhibitors in other cancers which will further propel the growth of market. For instance, Mekinist is being evaluated in phase-III for management of ovarian cancer or Koselugo is in phase-III for NSCLC patients and is expected to gain approval by end of 2022.
The future will see a dominance of combination therapy in MEK inhibitors market attributable to its high efficacy in comparison to monotherapy. Combinations of MEK inhibitors and targeted therapies appear to have specific promise in the setting of acquired resistance to targeted therapy, a pervasive challenge in the era of precision medicine. Moreover, the robust response of MEK inhibitors in combination with BRAF inhibitors in clinical practice has shown to significantly improve the outcomes in patients.
Apart from combing MEK inhibitors with other pathway inhibitors, studies are investigating the effect of MEK inhibition on the immune environment of tumors. Many clinical trials combining MEK inhibitor with immunotherapeutic agents are currently ongoing and have shown promising preclinical data. The promising early results of combinational treatment bring hope for further progress in the management of patients with cancer.
The overall MEK inhibitor market is highly competitive in nature, with leading players involved in regional expansion, partnerships, new product development, and research and development to increase market penetration. The key players in global MEK inhibitors market are Roche, Pfizer, AstraZeneca, Novartis, Cstone Therapeutics, and Ono Pharmaceuticals. Moreover, the pipeline of MEK inhibitors is highly crowded and the coming years will witness rapid approval of MEK inhibitors in management of wide range of cancers.
Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global MEK Inhibitors Market Opportunity Assessment: > USD 3 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 4 Drugs
- Approved MEK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
The identification of mitogen activated protein kinase (MAPK) signaling pathway and its critical role in the regulation of diverse cellular activities in the development of cancer including cell proliferation, survival, and differentiation have drawn the interest the researchers to inhibit the pathway as an alternative in the management of cancer. The MEK inhibitors were developed to specifically target the Ras/Ref/Me/Erk signaling pathway thus inhibiting cell proliferation, and inducing apoptosis.
To date, four MEK inhibitors have entered into the market which has shown high adoption rates by BRAF mutated cancer patients, mainly in melanoma. In addition to this, several other MEK inhibitors are present in the clinical trials. The potential candidates in the pipeline are AZD8330, NX-179, HL-085, E6201, Mirdametinib and Refametinib. These drugs have shown encouraging clinical response in their early studies and are expected to enter the market during the forthcoming years.
Apart from melanoma, several ongoing clinical trials are also ongoing which are accessing the role of MEK inhibitors in other cancers including non-small cell lung cancer, breast cancer, thyroid cancer, ovarian cancers and others. It is expected that the coming years will witness expanded approval of the approved MEK inhibitors in other cancers which will further propel the growth of market. For instance, Mekinist is being evaluated in phase-III for management of ovarian cancer or Koselugo is in phase-III for NSCLC patients and is expected to gain approval by end of 2022.
The future will see a dominance of combination therapy in MEK inhibitors market attributable to its high efficacy in comparison to monotherapy. Combinations of MEK inhibitors and targeted therapies appear to have specific promise in the setting of acquired resistance to targeted therapy, a pervasive challenge in the era of precision medicine. Moreover, the robust response of MEK inhibitors in combination with BRAF inhibitors in clinical practice has shown to significantly improve the outcomes in patients.
Apart from combing MEK inhibitors with other pathway inhibitors, studies are investigating the effect of MEK inhibition on the immune environment of tumors. Many clinical trials combining MEK inhibitor with immunotherapeutic agents are currently ongoing and have shown promising preclinical data. The promising early results of combinational treatment bring hope for further progress in the management of patients with cancer.
The overall MEK inhibitor market is highly competitive in nature, with leading players involved in regional expansion, partnerships, new product development, and research and development to increase market penetration. The key players in global MEK inhibitors market are Roche, Pfizer, AstraZeneca, Novartis, Cstone Therapeutics, and Ono Pharmaceuticals. Moreover, the pipeline of MEK inhibitors is highly crowded and the coming years will witness rapid approval of MEK inhibitors in management of wide range of cancers.
RESEARCH METHODOLOGY
1. INTRODUCTION TO MEK INHIBITORS
2. MEK INHIBITORS - MECHANISM OF ACTION
3. GLOBAL MEK INHIBITORS MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Key Drugs Candidates in Research & Development
3.3 Future Market Opportunity
4. GLOBAL MEK INHIBITORS MARKET TRENDS BY REGION
4.1 US
4.2 Europe
4.3 China
4.4 Japan
5. GLOBAL MEK INHIBITORS CLINICAL TRIALS INSIGHT
5.1 By Phase
5.2 By Status
5.3 By Region
6. MEKINIST (TRAMETINIB) – CLINICAL & SALES INSIGHT
6.1 Overview
6.2 Patents & Assignees
6.3 Dosage & Price Analysis
6.4 Sales Analysis
7. COTELLIC (COBIMETINIB) – CLINICAL & SALES INSIGHT
7.1 Overview
7.2 Patents & Assignees
7.3 Dosage & Price Analysis
7.4 Sales Analysis
8. MEKTOVI (BINIMETINIB) – CLINICAL & SALES INSIGHT
8.1 Overview
8.2 Patents & Assignees
8.3 Dosage & Price Analysis
8.4 Sales Analysis
9. KOSELUGO (SELUMITINIB) – CLINICAL & SALES INSIGHT
9.1 Overview
9.2 Patents & Assignees
9.3 Dosage & Price Analysis
9.4 Sales Analysis
10. MEK INHIBITORS SALES FORECAST 2026
10.1 Mekinist Sales Forecast
10.2 Cotellic Sales Forecast
10.3 Mektovi Sales Forecast
10.4 Koselugo Sales Analysis
11. MEK INHIBITORS MARKET OPPORTUNITY BY INDICATION
11.1 Melanoma
11.2 Lung Cancer
11.3 Colorectal Cancer
11.4 Thyroid Cancer
11.5 Breast Cancer
12. GLOBAL MEK INHIBITORS CLINICAL TRIALS INSIGHT – ACTIVE TRIALS
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-II/III
12.7 Registered
13. MARKETED MEK INHIBITORS DRUGS CLINICAL INSIGHT
14. GLOBAL MEK INHIBITORS MARKET FUTURE PERSPECTIVE
15. GLOBAL MEK INHIBITORS MARKET DYNAMICS
15.1 Favorable Market Parameters
15.2 Market Challenges
16. COMPETITIVE LANDSCAPE
16.1 AstraZeneca
16.2 Bristol Myers Squibb
16.3 CStone Therapeutics
16.4 GlaxoSmithKline
16.5 Immuneering
16.6 Merck
16.7 NFlection Therapeutics
16.8 Novartis
16.9 Ono Pharmaceutical
16.10 Pfizer
16.11 Roche
16.12 SpringWorks Therapeutics
1. INTRODUCTION TO MEK INHIBITORS
2. MEK INHIBITORS - MECHANISM OF ACTION
3. GLOBAL MEK INHIBITORS MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Key Drugs Candidates in Research & Development
3.3 Future Market Opportunity
4. GLOBAL MEK INHIBITORS MARKET TRENDS BY REGION
4.1 US
4.2 Europe
4.3 China
4.4 Japan
5. GLOBAL MEK INHIBITORS CLINICAL TRIALS INSIGHT
5.1 By Phase
5.2 By Status
5.3 By Region
6. MEKINIST (TRAMETINIB) – CLINICAL & SALES INSIGHT
6.1 Overview
6.2 Patents & Assignees
6.3 Dosage & Price Analysis
6.4 Sales Analysis
7. COTELLIC (COBIMETINIB) – CLINICAL & SALES INSIGHT
7.1 Overview
7.2 Patents & Assignees
7.3 Dosage & Price Analysis
7.4 Sales Analysis
8. MEKTOVI (BINIMETINIB) – CLINICAL & SALES INSIGHT
8.1 Overview
8.2 Patents & Assignees
8.3 Dosage & Price Analysis
8.4 Sales Analysis
9. KOSELUGO (SELUMITINIB) – CLINICAL & SALES INSIGHT
9.1 Overview
9.2 Patents & Assignees
9.3 Dosage & Price Analysis
9.4 Sales Analysis
10. MEK INHIBITORS SALES FORECAST 2026
10.1 Mekinist Sales Forecast
10.2 Cotellic Sales Forecast
10.3 Mektovi Sales Forecast
10.4 Koselugo Sales Analysis
11. MEK INHIBITORS MARKET OPPORTUNITY BY INDICATION
11.1 Melanoma
11.2 Lung Cancer
11.3 Colorectal Cancer
11.4 Thyroid Cancer
11.5 Breast Cancer
12. GLOBAL MEK INHIBITORS CLINICAL TRIALS INSIGHT – ACTIVE TRIALS
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-II/III
12.7 Registered
13. MARKETED MEK INHIBITORS DRUGS CLINICAL INSIGHT
14. GLOBAL MEK INHIBITORS MARKET FUTURE PERSPECTIVE
15. GLOBAL MEK INHIBITORS MARKET DYNAMICS
15.1 Favorable Market Parameters
15.2 Market Challenges
16. COMPETITIVE LANDSCAPE
16.1 AstraZeneca
16.2 Bristol Myers Squibb
16.3 CStone Therapeutics
16.4 GlaxoSmithKline
16.5 Immuneering
16.6 Merck
16.7 NFlection Therapeutics
16.8 Novartis
16.9 Ono Pharmaceutical
16.10 Pfizer
16.11 Roche
16.12 SpringWorks Therapeutics
LIST OF FIGURES
Figure 1-1: Approved MEK Inhibitors
Figure 2-1: MEK Inhibitors - Mechanism of Action
Figure 2-2: Trametinib - Mechanism of Action in Combinational Therapy
Figure 3-1: Global - Cancer Incidence (Million), 2020 & 2025
Figure 3-2: Global - Cancer Deaths (Million), 2020 & 2025
Figure 3-3: Global - MEK Inhibitor Market by Product (%), 2020
Figure 3-4: Global - MEK Inhibitor Market by Product (%), H1’2021
Figure 3-5: Global - MEK Inhibitor Market by Product (US$ Million), 2020
Figure 3-6: Global - MEK Inhibitor Market by Product (US$ Million), H1’2021
Figure 3-7: Global – MEK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 3-8: MEK Inhibitor Market by Region (US$ Million), 2020
Figure 3-9: MEK Inhibitor Market by Region (%), 2020
Figure 3-10: ROW – MEK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 4-1: US - Cancer Incidence (Million), 2020 & 2025
Figure 4-2: US - Cancer Deaths (Million), 2020 & 2025
Figure 4-3: MEK Inhibitor Market – US vs. ROW (US$ Million), 2020
Figure 4-4: MEK Inhibitor Market - US vs. ROW (%), 2020
Figure 4-5: US – MEK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 4-6: Europe - Cancer Incidence (Million), 2020 & 2025
Figure 4-7: Europe - Cancer Deaths (Million), 2020 & 2025
Figure 4-8: MET Inhibitor Market - Europe vs. ROW (US$ Million), 2020
Figure 4-9: MET Inhibitor Market - Europe vs. ROW (%), 2020
Figure 4-10: Europe – MEK Inhibitors Market Size (US$ Million), 2020 – 2026
Figure 4-11: China - Cancer Incidence (Million), 2020 & 2025
Figure 4-12: China - Cancer Deaths (Million), 2020 & 2025
Figure 4-13: MET Inhibitor Market - China vs. ROW (US$ Million), 2020
Figure 4-14: MET Inhibitor Market - China vs. ROW (%), 2020
Figure 4-15: China – MEK Inhibitors Market Size (US$ Million), 2020 – 2026
Figure 4-16: Japan - Cancer Incidence (Million), 2020 & 2025
Figure 4-17: Japan - Cancer Deaths (Million), 2020 & 2025
Figure 4-18: MET Inhibitor Market - Japan vs. ROW (US$ Million), 2020
Figure 4-19: MET Inhibitor Market - Japan vs. ROW (%), 2020
Figure 4-20: Japan – MEK Inhibitors Market Size (US$ Million), 2020 – 2026
Figure 5-1: Global - MEK Inhibitors Clinical Insights by Phase (Number of Trials), September’2021
Figure 5-2: Global - MEK Inhibitors Clinical Trials Insights by Phase (%), September’2021
Figure 5-3: Global - MEK Inhibitors Clinical Trials Insights by Status (Number of Trials), September’2021
Figure 5-4: Global - MEK Inhibitors Clinical Trials Insights by Status (%), September’2021
Figure 5-5: MEK Inhibitors – Clinical Trials Insights by Region (Number of Trials), September’2021
Figure 5-6: North America – MEK Inhibitors Clinical Trials by Countries (Number of Trials), September’2021
Figure 5-7: MEK Inhibitors – Clinical Trials Insights by Region (%), September’2021
Figure 5-8: North America – MEK Inhibitors Clinical Trials by Countries (%), September’2021
Figure 6-1: US – Mekinist FDA Approval History by Indication
Figure 6-2: Mekinist – Approval Year by Region
Figure 6-3: US – Mekinist Patents Assigned by Assignees
Figure 6-4: US – Mekinist Patent Approval & Expiration Year
Figure 6-5: Mekinist – Patent Exclusivity by Region
Figure 6-6: Mekinist – Cost of Supply of 30 Tablets & Per Unit Cost of 0.5mg Oral Tablet (US$), September’2021
Figure 6-7: Mekinist – Cost of Supply of 30 Tablets & Per Unit Cost of 2mg Oral Tablet (US$), September’2021
Figure 6-8: Mekinist – Recommended Initial & Dose Reductions (mg/day)
Figure 6-9: Mekinist – Average Daily, Monthly & Annual Treatment Cost (US$), September’2021
Figure 6-10: Global – Mekinist Annual Sales (US$ Million), 2018 – 2020
Figure 6-11: US – Mekinist Annual Sales (US$ Million), 2018 – 2020
Figure 6-12: ROW – Mekinist Annual Sales (US$ Million), 2018 – 2020
Figure 6-13: Mekinist - Annual Sales by Region (US$ Million), 2020
Figure 6-14: Mekinist - Annual Sales by Region (%), 2020
Figure 6-15: Global – Mekinist Quarterly Sales (US$ Million), 2020
Figure 6-16: US – Mekinist Quarterly Sales (US$ Million), 2020
Figure 6-17: ROW – Mekinist Quarterly Sales (US$ Million), 2020
Figure 6-18: Global – Mekinist Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 6-19: US – Mekinist Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 6-20: Mekinist – Half Year Sales (US$ Million) by Region, H1’2021
Figure 6-21: Mekinist – Half Year Sales by Region (%), 2021
Figure 7-1: Cotellic – Approval Year by Region
Figure 7-2: US – Cotellic Patent Approval & Expiration Year
Figure 7-3: Europe – Cotellic EMA Approval & Patent Exclusivity Year
Figure 7-4: Cotellic – Cost of Supply of 63 Tablets & Per Unit Cost of 20mg Oral Tablet (US$), September’2021
Figure 7-5: Cotellic – Recommended Initial & Dose Reductions (mg/day)
Figure 7-6: Coteliic – Average Daily, Monthly & Annual Treatment Cost (US$), September’2021
Figure 7-7: Global - Cotellic Annual Sales (CHF/US$ Million), 2018 - 2020
Figure 7-8: US - Cotellic Annual Sales (CHF/US$ Million), 2018 - 2020
Figure 7-9: Europe - Cotellic Annual Sales (CHF/US$ Million), 2018 - 2020
Figure 7-10: ROW - Cotellic Annual Sales (CHF/US$ Million), 2018 - 2020
Figure 7-11: Cotellic - Annual Sales by Region (CHF/US$ Million), 2020
Figure 7-12: Cotellic - Annual Sales by Region (%), 2020
Figure 7-13: Global - Cotellic Quarterly Sales (CHF/US$ Million), Q1 & Q2'2021
Figure 7-14: US - Cotellic Quarterly Sales (CHF/US$ Million), Q1 & Q2'2021
Figure 7-15: Europe – Cotellic Quarterly Sales (CHF/US$ Million), Q1 & Q2'2021
Figure 7-16: ROW - Cotellic Quarterly Sales (CHF/US$ Million), Q1 & Q2'2021
Figure 7-17: Cotellic - Half Year Sales by Region (CHF/US$ Million), H1’2021
Figure 7-18: Cotellic - Half Year Sales by Region (%), H1’2021
Figure 8-1: Mektovi – Approval Year by Region
Figure 8-2: Japan - Mektovi Approval Year by Indication
Figure 8-3: US – Mektovi Patents Assigned by Assignees
Figure 8-4: US – Mektovi Patent Approval & Expiration Year
Figure 8-5: Mektovi – Cost of Supply of 180 Tablets & Per Unit Cost of 15mg Oral Tablet (US$), September’2021
Figure 8-6: Mektovi – Recommended Initial & Dose Reductions (mg/day)
Figure 8-7: Mektovi – Average Daily, Monthly & Annual Treatment Cost (US$), September’2021
Figure 8-8: Global – Mektovi Annual Sales (US$ Million), 2019 & 2020
Figure 8-9: Global – Mektovi Quarterly Sales (US$ Million), 2020
Figure 8-10: Global – Mektovi Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 9-1: Koselugo – Approval Year by Region
Figure 9-2: US – Koselugo Patent Approval & Expiration Year
Figure 9-3: Koselugo – Cost of Supply of 28 Capsules & Per Unit Cost of 10mg Oral Capsule (US$), September’2021
Figure 9-4: Koselugo – Cost of Supply of 60 Capsules & Per Unit Cost of 10mg Oral Capsule (US$), September’2021
Figure 9-5: Koselugo – Cost of Supply of 28 Capsules & Per Unit Cost of 25mg Oral Capsule (US$), September’2021
Figure 9-6: Koselugo – Cost of Supply of 60 Capsules & Per Unit Cost of 25mg Oral Capsule (US$), September’2021
Figure 9-7: Global – Koselugo Quarterly Sales (US$ Million), Q2-Q4’2020
Figure 9-8: Global – Koselugo Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 10-1: Global - Mekinist Sales Forecast (US$ Million), 2021-2026
Figure 10-2: US - Mekinist Sales Forecast (US$ Million), 2021-2026
Figure 10-3: ROW - Mekinist Sales Forecast (US$ Million), 2021-2026
Figure 10-4: Global - Cotellic Sales Forecast (US$ Million), 2021-2026
Figure 10-5: US - Cotellic Sales Forecast (US$ Million), 2021-2026
Figure 10-6: Europe - Cotellic Sales Forecast (US$ Million), 2021-2026
Figure 10-7: ROW - Cotellic Sales Forecast (US$ Million), 2021-2026
Figure 10-8: Global – Mektovi Sales Forecast (US$ Million), 2021 - 2026
Figure 10-9: Global – Koselugo Sales Forecast (US$ Million), 2021 - 2026
Figure 11-1: Global – Estimated Melanoma Incidences, 2020 - 2026
Figure 11-2: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Melanoma Patients, 2021-2026
Figure 11-3: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Melanoma Patients, 2021-2026
Figure 11-4: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Melanoma Patients, 2021-2026
Figure 11-5: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Melanoma Patients, 2021-2026
Figure 11-6: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Melanoma Patients, 2021-2026
Figure 11-7: Global – MEK Inhibitor Therapy Adoption Rate by 12% of Total Melanoma Patients, 2021-2026
Figure 11-8: Global – MEK Inhibitor Therapy Adoption Rate by 14% of Total Melanoma Patients, 2021-2026
Figure 11-9: Global – MEK Inhibitor Therapy Adoption Rate by 16% of Total Melanoma Patients, 2021-2026
Figure 11-10: Global – MEK Inhibitor Therapy Adoption Rate by 18% of Total Melanoma Patients, 2021-2026
Figure 11-11: Global – MEK Inhibitor Therapy Adoption Rate by 20% of Total Melanoma Patients, 2021-2026
Figure 11-12: Global – Estimated Lung Cancer Incidences, 2020 - 2026
Figure 11-13: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Lung Cancer Patients, 2021-2026
Figure 11-14: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Lung Cancer Patients, 2021-2026
Figure 11-15: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Lung Cancer Patients, 2021-2026
Figure 11-16: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Lung Cancer Patients, 2021-2026
Figure 11-17: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Lung Cancer Patients, 2021-2026
Figure 11-18: Global – MEK Inhibitor Therapy Adoption Rate by 12% of Total Lung Cancer Patients, 2021-2026
Figure 11-19: Global – MEK Inhibitor Therapy Adoption Rate by 14% of Total Lung Cancer Patients, 2021-2026
Figure 11-20: Global – MEK Inhibitor Therapy Adoption Rate by 16% of Total Lung Cancer Patients, 2021-2026
Figure 11-21: Global – MEK Inhibitor Therapy Adoption Rate by 18% of Total Lung Cancer Patients, 2021-2026
Figure 11-22: Global – MEK Inhibitor Therapy Adoption Rate by 20% of Total Lung Cancer Patients, 2021-2026
Figure 11-23: Global – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-24: Global – MEK Inhibitor Therapy Adoption Rate by 1% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-25: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-26: Global – MEK Inhibitor Therapy Adoption Rate by 3% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-27: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-28: Global – MEK Inhibitor Therapy Adoption Rate by 5% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-29: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-30: Global – MEK Inhibitor Therapy Adoption Rate by 7% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-31: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-32: Global – MEK Inhibitor Therapy Adoption Rate by 9% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-33: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-34: Global – Estimated Thyroid Cancer Cases, 2020-2026
Figure 11-35: Global – MEK Inhibitor Therapy Adoption Rate by 1% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-36: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-37: Global – MEK Inhibitor Therapy Adoption Rate by 3% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-38: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-39: Global – MEK Inhibitor Therapy Adoption Rate by 5% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-40: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-41: Global – MEK Inhibitor Therapy Adoption Rate by 7% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-42: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-43: Global – MEK Inhibitor Therapy Adoption Rate by 9% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-44: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-45: Global – Estimated Thyroid Cancer Cases, 2020-2026
Figure 11-46: Global – MEK Inhibitor Therapy Adoption Rate by 1% of Total Breast Cancer Patients, 2021-2026
Figure 11-47: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Breast Cancer Patients, 2021-2026
Figure 11-48: Global – MEK Inhibitor Therapy Adoption Rate by 3% of Total Breast Cancer Patients, 2021-2026
Figure 11-49: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Breast Cancer Patients, 2021-2026
Figure 11-50: Global – MEK Inhibitor Therapy Adoption Rate by 5% of Total Breast Cancer Patients, 2021-2026
Figure 11-51: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Breast Cancer Patients, 2021-2026
Figure 11-52: Global – MEK Inhibitor Therapy Adoption Rate by 7% of Total Breast Cancer Patients, 2021-2026
Figure 11-53: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Breast Cancer Patients, 2021-2026
Figure 11-54: Global – MEK Inhibitor Therapy Adoption Rate by 9% of Total Breast Cancer Patients, 2021-2026
Figure 11-55: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Breast Cancer Patients, 2021-2026
Figure 12-1: Global – Number of MEK Inhibitors Drug In Clinical Trials By Phase’September’2021
Figure 15-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 15-2: Global - MET Inhibitor Market Favorable Parameters
Figure 15-3: US – Average Monthly Cost & Annual Cost of Treatment with Vemurafenib & Cobimetinib (US$), 2020
Figure 15-4: US – Average Monthly Cost & Annual Cost of Treatment with Dabrafenib & Trametinib (US$), 2020
Figure 15-5: Global - MEK Inhibitor Market Challenges
Figure 1-1: Approved MEK Inhibitors
Figure 2-1: MEK Inhibitors - Mechanism of Action
Figure 2-2: Trametinib - Mechanism of Action in Combinational Therapy
Figure 3-1: Global - Cancer Incidence (Million), 2020 & 2025
Figure 3-2: Global - Cancer Deaths (Million), 2020 & 2025
Figure 3-3: Global - MEK Inhibitor Market by Product (%), 2020
Figure 3-4: Global - MEK Inhibitor Market by Product (%), H1’2021
Figure 3-5: Global - MEK Inhibitor Market by Product (US$ Million), 2020
Figure 3-6: Global - MEK Inhibitor Market by Product (US$ Million), H1’2021
Figure 3-7: Global – MEK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 3-8: MEK Inhibitor Market by Region (US$ Million), 2020
Figure 3-9: MEK Inhibitor Market by Region (%), 2020
Figure 3-10: ROW – MEK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 4-1: US - Cancer Incidence (Million), 2020 & 2025
Figure 4-2: US - Cancer Deaths (Million), 2020 & 2025
Figure 4-3: MEK Inhibitor Market – US vs. ROW (US$ Million), 2020
Figure 4-4: MEK Inhibitor Market - US vs. ROW (%), 2020
Figure 4-5: US – MEK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 4-6: Europe - Cancer Incidence (Million), 2020 & 2025
Figure 4-7: Europe - Cancer Deaths (Million), 2020 & 2025
Figure 4-8: MET Inhibitor Market - Europe vs. ROW (US$ Million), 2020
Figure 4-9: MET Inhibitor Market - Europe vs. ROW (%), 2020
Figure 4-10: Europe – MEK Inhibitors Market Size (US$ Million), 2020 – 2026
Figure 4-11: China - Cancer Incidence (Million), 2020 & 2025
Figure 4-12: China - Cancer Deaths (Million), 2020 & 2025
Figure 4-13: MET Inhibitor Market - China vs. ROW (US$ Million), 2020
Figure 4-14: MET Inhibitor Market - China vs. ROW (%), 2020
Figure 4-15: China – MEK Inhibitors Market Size (US$ Million), 2020 – 2026
Figure 4-16: Japan - Cancer Incidence (Million), 2020 & 2025
Figure 4-17: Japan - Cancer Deaths (Million), 2020 & 2025
Figure 4-18: MET Inhibitor Market - Japan vs. ROW (US$ Million), 2020
Figure 4-19: MET Inhibitor Market - Japan vs. ROW (%), 2020
Figure 4-20: Japan – MEK Inhibitors Market Size (US$ Million), 2020 – 2026
Figure 5-1: Global - MEK Inhibitors Clinical Insights by Phase (Number of Trials), September’2021
Figure 5-2: Global - MEK Inhibitors Clinical Trials Insights by Phase (%), September’2021
Figure 5-3: Global - MEK Inhibitors Clinical Trials Insights by Status (Number of Trials), September’2021
Figure 5-4: Global - MEK Inhibitors Clinical Trials Insights by Status (%), September’2021
Figure 5-5: MEK Inhibitors – Clinical Trials Insights by Region (Number of Trials), September’2021
Figure 5-6: North America – MEK Inhibitors Clinical Trials by Countries (Number of Trials), September’2021
Figure 5-7: MEK Inhibitors – Clinical Trials Insights by Region (%), September’2021
Figure 5-8: North America – MEK Inhibitors Clinical Trials by Countries (%), September’2021
Figure 6-1: US – Mekinist FDA Approval History by Indication
Figure 6-2: Mekinist – Approval Year by Region
Figure 6-3: US – Mekinist Patents Assigned by Assignees
Figure 6-4: US – Mekinist Patent Approval & Expiration Year
Figure 6-5: Mekinist – Patent Exclusivity by Region
Figure 6-6: Mekinist – Cost of Supply of 30 Tablets & Per Unit Cost of 0.5mg Oral Tablet (US$), September’2021
Figure 6-7: Mekinist – Cost of Supply of 30 Tablets & Per Unit Cost of 2mg Oral Tablet (US$), September’2021
Figure 6-8: Mekinist – Recommended Initial & Dose Reductions (mg/day)
Figure 6-9: Mekinist – Average Daily, Monthly & Annual Treatment Cost (US$), September’2021
Figure 6-10: Global – Mekinist Annual Sales (US$ Million), 2018 – 2020
Figure 6-11: US – Mekinist Annual Sales (US$ Million), 2018 – 2020
Figure 6-12: ROW – Mekinist Annual Sales (US$ Million), 2018 – 2020
Figure 6-13: Mekinist - Annual Sales by Region (US$ Million), 2020
Figure 6-14: Mekinist - Annual Sales by Region (%), 2020
Figure 6-15: Global – Mekinist Quarterly Sales (US$ Million), 2020
Figure 6-16: US – Mekinist Quarterly Sales (US$ Million), 2020
Figure 6-17: ROW – Mekinist Quarterly Sales (US$ Million), 2020
Figure 6-18: Global – Mekinist Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 6-19: US – Mekinist Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 6-20: Mekinist – Half Year Sales (US$ Million) by Region, H1’2021
Figure 6-21: Mekinist – Half Year Sales by Region (%), 2021
Figure 7-1: Cotellic – Approval Year by Region
Figure 7-2: US – Cotellic Patent Approval & Expiration Year
Figure 7-3: Europe – Cotellic EMA Approval & Patent Exclusivity Year
Figure 7-4: Cotellic – Cost of Supply of 63 Tablets & Per Unit Cost of 20mg Oral Tablet (US$), September’2021
Figure 7-5: Cotellic – Recommended Initial & Dose Reductions (mg/day)
Figure 7-6: Coteliic – Average Daily, Monthly & Annual Treatment Cost (US$), September’2021
Figure 7-7: Global - Cotellic Annual Sales (CHF/US$ Million), 2018 - 2020
Figure 7-8: US - Cotellic Annual Sales (CHF/US$ Million), 2018 - 2020
Figure 7-9: Europe - Cotellic Annual Sales (CHF/US$ Million), 2018 - 2020
Figure 7-10: ROW - Cotellic Annual Sales (CHF/US$ Million), 2018 - 2020
Figure 7-11: Cotellic - Annual Sales by Region (CHF/US$ Million), 2020
Figure 7-12: Cotellic - Annual Sales by Region (%), 2020
Figure 7-13: Global - Cotellic Quarterly Sales (CHF/US$ Million), Q1 & Q2'2021
Figure 7-14: US - Cotellic Quarterly Sales (CHF/US$ Million), Q1 & Q2'2021
Figure 7-15: Europe – Cotellic Quarterly Sales (CHF/US$ Million), Q1 & Q2'2021
Figure 7-16: ROW - Cotellic Quarterly Sales (CHF/US$ Million), Q1 & Q2'2021
Figure 7-17: Cotellic - Half Year Sales by Region (CHF/US$ Million), H1’2021
Figure 7-18: Cotellic - Half Year Sales by Region (%), H1’2021
Figure 8-1: Mektovi – Approval Year by Region
Figure 8-2: Japan - Mektovi Approval Year by Indication
Figure 8-3: US – Mektovi Patents Assigned by Assignees
Figure 8-4: US – Mektovi Patent Approval & Expiration Year
Figure 8-5: Mektovi – Cost of Supply of 180 Tablets & Per Unit Cost of 15mg Oral Tablet (US$), September’2021
Figure 8-6: Mektovi – Recommended Initial & Dose Reductions (mg/day)
Figure 8-7: Mektovi – Average Daily, Monthly & Annual Treatment Cost (US$), September’2021
Figure 8-8: Global – Mektovi Annual Sales (US$ Million), 2019 & 2020
Figure 8-9: Global – Mektovi Quarterly Sales (US$ Million), 2020
Figure 8-10: Global – Mektovi Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 9-1: Koselugo – Approval Year by Region
Figure 9-2: US – Koselugo Patent Approval & Expiration Year
Figure 9-3: Koselugo – Cost of Supply of 28 Capsules & Per Unit Cost of 10mg Oral Capsule (US$), September’2021
Figure 9-4: Koselugo – Cost of Supply of 60 Capsules & Per Unit Cost of 10mg Oral Capsule (US$), September’2021
Figure 9-5: Koselugo – Cost of Supply of 28 Capsules & Per Unit Cost of 25mg Oral Capsule (US$), September’2021
Figure 9-6: Koselugo – Cost of Supply of 60 Capsules & Per Unit Cost of 25mg Oral Capsule (US$), September’2021
Figure 9-7: Global – Koselugo Quarterly Sales (US$ Million), Q2-Q4’2020
Figure 9-8: Global – Koselugo Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 10-1: Global - Mekinist Sales Forecast (US$ Million), 2021-2026
Figure 10-2: US - Mekinist Sales Forecast (US$ Million), 2021-2026
Figure 10-3: ROW - Mekinist Sales Forecast (US$ Million), 2021-2026
Figure 10-4: Global - Cotellic Sales Forecast (US$ Million), 2021-2026
Figure 10-5: US - Cotellic Sales Forecast (US$ Million), 2021-2026
Figure 10-6: Europe - Cotellic Sales Forecast (US$ Million), 2021-2026
Figure 10-7: ROW - Cotellic Sales Forecast (US$ Million), 2021-2026
Figure 10-8: Global – Mektovi Sales Forecast (US$ Million), 2021 - 2026
Figure 10-9: Global – Koselugo Sales Forecast (US$ Million), 2021 - 2026
Figure 11-1: Global – Estimated Melanoma Incidences, 2020 - 2026
Figure 11-2: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Melanoma Patients, 2021-2026
Figure 11-3: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Melanoma Patients, 2021-2026
Figure 11-4: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Melanoma Patients, 2021-2026
Figure 11-5: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Melanoma Patients, 2021-2026
Figure 11-6: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Melanoma Patients, 2021-2026
Figure 11-7: Global – MEK Inhibitor Therapy Adoption Rate by 12% of Total Melanoma Patients, 2021-2026
Figure 11-8: Global – MEK Inhibitor Therapy Adoption Rate by 14% of Total Melanoma Patients, 2021-2026
Figure 11-9: Global – MEK Inhibitor Therapy Adoption Rate by 16% of Total Melanoma Patients, 2021-2026
Figure 11-10: Global – MEK Inhibitor Therapy Adoption Rate by 18% of Total Melanoma Patients, 2021-2026
Figure 11-11: Global – MEK Inhibitor Therapy Adoption Rate by 20% of Total Melanoma Patients, 2021-2026
Figure 11-12: Global – Estimated Lung Cancer Incidences, 2020 - 2026
Figure 11-13: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Lung Cancer Patients, 2021-2026
Figure 11-14: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Lung Cancer Patients, 2021-2026
Figure 11-15: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Lung Cancer Patients, 2021-2026
Figure 11-16: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Lung Cancer Patients, 2021-2026
Figure 11-17: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Lung Cancer Patients, 2021-2026
Figure 11-18: Global – MEK Inhibitor Therapy Adoption Rate by 12% of Total Lung Cancer Patients, 2021-2026
Figure 11-19: Global – MEK Inhibitor Therapy Adoption Rate by 14% of Total Lung Cancer Patients, 2021-2026
Figure 11-20: Global – MEK Inhibitor Therapy Adoption Rate by 16% of Total Lung Cancer Patients, 2021-2026
Figure 11-21: Global – MEK Inhibitor Therapy Adoption Rate by 18% of Total Lung Cancer Patients, 2021-2026
Figure 11-22: Global – MEK Inhibitor Therapy Adoption Rate by 20% of Total Lung Cancer Patients, 2021-2026
Figure 11-23: Global – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-24: Global – MEK Inhibitor Therapy Adoption Rate by 1% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-25: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-26: Global – MEK Inhibitor Therapy Adoption Rate by 3% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-27: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-28: Global – MEK Inhibitor Therapy Adoption Rate by 5% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-29: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-30: Global – MEK Inhibitor Therapy Adoption Rate by 7% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-31: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-32: Global – MEK Inhibitor Therapy Adoption Rate by 9% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-33: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Colorectal Cancer Patients, 2021-2026
Figure 11-34: Global – Estimated Thyroid Cancer Cases, 2020-2026
Figure 11-35: Global – MEK Inhibitor Therapy Adoption Rate by 1% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-36: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-37: Global – MEK Inhibitor Therapy Adoption Rate by 3% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-38: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-39: Global – MEK Inhibitor Therapy Adoption Rate by 5% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-40: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-41: Global – MEK Inhibitor Therapy Adoption Rate by 7% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-42: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-43: Global – MEK Inhibitor Therapy Adoption Rate by 9% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-44: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Thyroid Cancer Patients, 2021-2026
Figure 11-45: Global – Estimated Thyroid Cancer Cases, 2020-2026
Figure 11-46: Global – MEK Inhibitor Therapy Adoption Rate by 1% of Total Breast Cancer Patients, 2021-2026
Figure 11-47: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Breast Cancer Patients, 2021-2026
Figure 11-48: Global – MEK Inhibitor Therapy Adoption Rate by 3% of Total Breast Cancer Patients, 2021-2026
Figure 11-49: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Breast Cancer Patients, 2021-2026
Figure 11-50: Global – MEK Inhibitor Therapy Adoption Rate by 5% of Total Breast Cancer Patients, 2021-2026
Figure 11-51: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Breast Cancer Patients, 2021-2026
Figure 11-52: Global – MEK Inhibitor Therapy Adoption Rate by 7% of Total Breast Cancer Patients, 2021-2026
Figure 11-53: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Breast Cancer Patients, 2021-2026
Figure 11-54: Global – MEK Inhibitor Therapy Adoption Rate by 9% of Total Breast Cancer Patients, 2021-2026
Figure 11-55: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Breast Cancer Patients, 2021-2026
Figure 12-1: Global – Number of MEK Inhibitors Drug In Clinical Trials By Phase’September’2021
Figure 15-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 15-2: Global - MET Inhibitor Market Favorable Parameters
Figure 15-3: US – Average Monthly Cost & Annual Cost of Treatment with Vemurafenib & Cobimetinib (US$), 2020
Figure 15-4: US – Average Monthly Cost & Annual Cost of Treatment with Dabrafenib & Trametinib (US$), 2020
Figure 15-5: Global - MEK Inhibitor Market Challenges
